Jazz Zepzelca-Tecentriq Combo Granted U.S. FDA Priority Review

 Target Action (PDUFA) Date set for October 7, 2025

Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting

Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca data

Webcast Details
IMforte trial results were first presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The Lancet. The Company will host an investor webcast on June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review these data. The webcast will include commentary from a leading small cell lung cancer expert and Company senior management. The webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.    

https://www.prnewswire.com/news-releases/zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-granted-us-fda-priority-review-for-first-line-maintenance-treatment-of-extensive-stage-small-cell-lung-cancer-302477581.html